US Food and Drug Administration (FDA) has accepted for filing Orexigen Therapeutics, Inc's New Drug Application (NDA) for Contrave (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity. The NDA is based on a substantial body of evidence gathered through the Contrave Obesity Research (COR) clinical programme, which included over 4,500 patients.

"We are pleased the US FDA has accepted our NDA for filing and look forward to working with the Agency during the review process," said Michael Narachi, president and CEO of Orexigen. "If approved, we believe Contrave will become an important therapeutic option for obese patients, making weight loss and weight maintenance an achievable cornerstone in the treatment of obesity and its common co-morbidities."

Contrave is an investigational combination therapy believed to address both physiological and behavioural drivers of obesity.

Orexigen Therapeutics is a biopharmaceutical company focused on the treatment of obesity.